Maria I. Fominykh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria I. Fominykh has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Ludmila P. Evstigneeva
Ural State Medical University
4 shared publications - Ekaterina Nailyevna Dudinskaya
Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications - Ksenia Belova
Ural Federal University
2 shared publications - Ol'Ga Mikhaylovna Lesnyak
Department of Family Medicine, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg 195298, Russia
2 shared publications - A. A. Bondareva
RUDN University
1 shared publication - A. E. Kolesnikov
Kazan City Clinical Hospital № 16
1 shared publication
Latest Publications
- 31 March 2026
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 14 (1)
Characteristics of Patients with Secondary Osteoporotic Fractures: Risk Factors, Diagnosis, and Treatment According to PROMETHEUS Registry Data
BACKGROUND: Individuals who have suffered fragility fractures, deserve special attention. Diagnosis and treatment of such patients remain unsatisfactory. To address this issue, in 2012, the Russian Association for Osteoporosis initiated the PROMETHEUS project (abbreviation of Russian expression ‘creation of services for secondary fractures prevention in patients with osteoporosis’) aimed to improve the prevention of secondary fractures. AIM: To analyze the incidence rate of previous osteoporotic fractures in patients aged 50 years and older enrolled in the Secondary Fracture Prevention Service (SFPS) evaluate their risk factors, identify if these patients had been previously diagnosed with osteoporosis and received anti-osteoporotic treatment. METHODS: A continuous, cross-sectional, multicenter, observational case-control study was conducted. The study group consisted of patients with a history of any fragility fractures (apart from the ‘index’ fracture). The control group included patients who did not report any previous fractures. Risk factors, diagnosis, and anti-osteoporotic therapy were analyzed. RESULTS: During the study period, 991 patients were enrolled in the registry. Of these, 443 (44.7%) had a history of fragility fractures. The number of previous fractures per patient ranged from 1 to 11, with 273 (61.62%) patients having one previous fracture and 103 (23.25%) having two. Risk factors for fracture include disability (OR 1.67, 95% CI 1.22–2.30), thyrotoxicosis (OR 2.90, 95% CI 1.12–7.47), and chronic obstructive pulmonary disease (OR 2.81, 95% CI 1.00–7.95). CONCLUSION: Almost half of the patients included in SFPS had a history of previous fragility fractures. However, the frequency of diagnosing osteoporosis after the previous fracture and use of anti-osteoporotic drugs were quite low, which necessitates further improvements of medical care for elderly patients with osteoporotic fractures, as well as the wide introduction of SFPS, its integration in the primary care setting, and inclusion in educational programs for traumatologists and primary care physicians.
- 31 March 2026
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 14 (1)
Characteristics of Patients with Secondary Osteoporotic Fractures: Risk Factors, Diagnosis, and Treatment According to PROMETHEUS Registry Data
BACKGROUND: Individuals who have suffered fragility fractures, deserve special attention. Diagnosis and treatment of such patients remain unsatisfactory. To address this issue, in 2012, the Russian Association for Osteoporosis initiated the PROMETHEUS project (abbreviation of Russian expression ‘creation of services for secondary fractures prevention in patients with osteoporosis’) aimed to improve the prevention of secondary fractures. AIM: To analyze the incidence rate of previous osteoporotic fractures in patients aged 50 years and older enrolled in the Secondary Fracture Prevention Service (SFPS) evaluate their risk factors, identify if these patients had been previously diagnosed with osteoporosis and received anti-osteoporotic treatment. METHODS: A continuous, cross-sectional, multicenter, observational case-control study was conducted. The study group consisted of patients with a history of any fragility fractures (apart from the ‘index’ fracture). The control group included patients who did not report any previous fractures. Risk factors, diagnosis, and anti-osteoporotic therapy were analyzed. RESULTS: During the study period, 991 patients were enrolled in the registry. Of these, 443 (44.7%) had a history of fragility fractures. The number of previous fractures per patient ranged from 1 to 11, with 273 (61.62%) patients having one previous fracture and 103 (23.25%) having two. Risk factors for fracture include disability (OR 1.67, 95% CI 1.22–2.30), thyrotoxicosis (OR 2.90, 95% CI 1.12–7.47), and chronic obstructive pulmonary disease (OR 2.81, 95% CI 1.00–7.95). CONCLUSION: Almost half of the patients included in SFPS had a history of previous fragility fractures. However, the frequency of diagnosing osteoporosis after the previous fracture and use of anti-osteoporotic drugs were quite low, which necessitates further improvements of medical care for elderly patients with osteoporotic fractures, as well as the wide introduction of SFPS, its integration in the primary care setting, and inclusion in educational programs for traumatologists and primary care physicians.
- 29 September 2025
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (3) , 70-77
Medical and social consequences of osteoporotic proximal femoral fracture in residents of Yekaterinburg
BACKGROUND: The most severe complication of osteoporosis is a fracture of the proximal femur. High mortality, disability, and economic costs determine the significance of fractures at this site for healthcare. Repeat fractures following a proximal femoral fracture, associated with low levels of osteoporosis diagnosis and treatment, play a significant role in adverse outcomes. AIM: To assess the medical and social consequences of osteoporotic proximal femoral fractures and the frequency of secondary fractures, as well as the rate of osteoporosis detection and treatment in individuals at high risk of fractures, in order to inform subsequent changes in healthcare delivery approaches for this patient category. METHODS: A retrospective cohort study was conducted of patients aged 50 years and older, hospitalized at the Traumatology Department of Yekaterinburg Central City Clinical Hospital No. 23 during 2021 with a diagnosis of “proximal femoral fracture.” The study was performed in two stages. The first stage involved assessing surgical activity and in-hospital mortality in patients with osteoporotic proximal femoral fractures over a 12-month period. The second stage consisted of assessing the medical and social consequences, the detection and treatment of osteoporosis, and the frequency of repeat osteoporotic fractures one year after the proximal femoral fracture. RESULTS: The study included 514 patients with osteoporotic proximal femoral fractures. Of these, 72 (14%) individuals were transferred to hospitals repurposed for the treatment of the novel coronavirus infection. Surgical treatment was performed on 396 (89.6%) patients: arthroplasty — 157 (39.6%), osteosynthesis — 239 (60.4%). One year after the proximal femoral fracture, 351 (75.3%) were alive, and 115 (24.7%) had died. Medical and social consequences of the proximal femoral fracture were known for 178 individuals. Of these, 5.6% of patients remained immobilized, 53.4% had their activity limited to their apartment, and 41% had resumed an active lifestyle. Repeat fractures within one year occurred in 15.7% of patients. Only 10 (5.6%) individuals were taking anti-osteoporotic medication. CONCLUSION: The assessment of medical care for osteoporotic proximal femoral fractures showed satisfactory surgical activity, which led to a reduction in mortality after fractures at this site, but also revealed delayed timing of surgical treatment. Insufficient attention to osteoporosis as a cause of fractures and the rare prescription of anti-osteoporotic drugs were identified, indicating the necessity of implementing a system for the prevention of repeat fractures.
- 29 September 2025
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (3) , 70-77
Medical and social consequences of osteoporotic proximal femoral fracture in residents of Yekaterinburg
BACKGROUND: The most severe complication of osteoporosis is a fracture of the proximal femur. High mortality, disability, and economic costs determine the significance of fractures at this site for healthcare. Repeat fractures following a proximal femoral fracture, associated with low levels of osteoporosis diagnosis and treatment, play a significant role in adverse outcomes. AIM: To assess the medical and social consequences of osteoporotic proximal femoral fractures and the frequency of secondary fractures, as well as the rate of osteoporosis detection and treatment in individuals at high risk of fractures, in order to inform subsequent changes in healthcare delivery approaches for this patient category. METHODS: A retrospective cohort study was conducted of patients aged 50 years and older, hospitalized at the Traumatology Department of Yekaterinburg Central City Clinical Hospital No. 23 during 2021 with a diagnosis of “proximal femoral fracture.” The study was performed in two stages. The first stage involved assessing surgical activity and in-hospital mortality in patients with osteoporotic proximal femoral fractures over a 12-month period. The second stage consisted of assessing the medical and social consequences, the detection and treatment of osteoporosis, and the frequency of repeat osteoporotic fractures one year after the proximal femoral fracture. RESULTS: The study included 514 patients with osteoporotic proximal femoral fractures. Of these, 72 (14%) individuals were transferred to hospitals repurposed for the treatment of the novel coronavirus infection. Surgical treatment was performed on 396 (89.6%) patients: arthroplasty — 157 (39.6%), osteosynthesis — 239 (60.4%). One year after the proximal femoral fracture, 351 (75.3%) were alive, and 115 (24.7%) had died. Medical and social consequences of the proximal femoral fracture were known for 178 individuals. Of these, 5.6% of patients remained immobilized, 53.4% had their activity limited to their apartment, and 41% had resumed an active lifestyle. Repeat fractures within one year occurred in 15.7% of patients. Only 10 (5.6%) individuals were taking anti-osteoporotic medication. CONCLUSION: The assessment of medical care for osteoporotic proximal femoral fractures showed satisfactory surgical activity, which led to a reduction in mortality after fractures at this site, but also revealed delayed timing of surgical treatment. Insufficient attention to osteoporosis as a cause of fractures and the rare prescription of anti-osteoporotic drugs were identified, indicating the necessity of implementing a system for the prevention of repeat fractures.
- Open Access
- 27 August 2025
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 24 (4) , 55-66
Features of the Lipid Profile in Patients after Acute Pulmonary Embolism
Introduction. The question of the effect of lipids on the risk of venous thromboembolism (VTE) currently remains open and debatable. The effect of dyslipidemia on the risk of arterial and venous thrombosis is currently being studied.The aim of the work was to evaluate the parameters of the blood lipids of patients with pulmonary embolism (PE) in the acute period and 1 year after the episode.Materials and methods. A prospective cohort study of lipids — total cholesterol (TCH), low-density lipoproteins (LDL-C), high-density lipoproteins (HDL-C), triglycerides (TG), apolipoproteins A1and B (ApoA1 and ApoB) — was conducted in patients in the acute period PE and after 1 year of follow-up.Results. Patients with PE in the acute period have initially normal levels of THC, LDL-C, TG, ApoA1, ApoB, and low levels of HDL-C. After 1 year of follow-up, the levels of THC, LDL-C, TG, and ApoB exceed normal values, dyslipidemia is detected due to the predominance of LDL-C, and HDL-C levels return to normal.Discussion. Determination of the blood lipids initially and over time allows monitoring changes in the concentration of lipids and correcting dyslipidemia to reduce cardiovascular risk.Conclusion. In the acute period of PE, normal levels of THC, LDL-C, TG, ApoA1, ApoB are noted, but lower in comparison with patients without a history of VTE, low levels of HDL-C. After a year of follow-up, hypercholesterolemia, dyslipidemia due to LDL-C, TG, and ApoB are detected, which creates a cardiovascular risk in these patients and requires correction.
- 27 August 2025
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 24 (4) , 55-66
Open AccessFeatures of the Lipid Profile in Patients after Acute Pulmonary Embolism
Introduction. The question of the effect of lipids on the risk of venous thromboembolism (VTE) currently remains open and debatable. The effect of dyslipidemia on the risk of arterial and venous thrombosis is currently being studied.The aim of the work was to evaluate the parameters of the blood lipids of patients with pulmonary embolism (PE) in the acute period and 1 year after the episode.Materials and methods. A prospective cohort study of lipids — total cholesterol (TCH), low-density lipoproteins (LDL-C), high-density lipoproteins (HDL-C), triglycerides (TG), apolipoproteins A1and B (ApoA1 and ApoB) — was conducted in patients in the acute period PE and after 1 year of follow-up.Results. Patients with PE in the acute period have initially normal levels of THC, LDL-C, TG, ApoA1, ApoB, and low levels of HDL-C. After 1 year of follow-up, the levels of THC, LDL-C, TG, and ApoB exceed normal values, dyslipidemia is detected due to the predominance of LDL-C, and HDL-C levels return to normal.Discussion. Determination of the blood lipids initially and over time allows monitoring changes in the concentration of lipids and correcting dyslipidemia to reduce cardiovascular risk.Conclusion. In the acute period of PE, normal levels of THC, LDL-C, TG, ApoA1, ApoB are noted, but lower in comparison with patients without a history of VTE, low levels of HDL-C. After a year of follow-up, hypercholesterolemia, dyslipidemia due to LDL-C, TG, and ApoB are detected, which creates a cardiovascular risk in these patients and requires correction.
- Open Access
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 27 (1) , 4-9
The consensus of experts of the russian association for osteoporosis on the long-term treatment of osteoporosis with bisphosphonates
Bisphosphonates are the most commonly used drugs for the treatment of osteoporosis and reducing the risk of fractures, which were introduced into clinical practice more than 30 years ago. The bisphosphonate group includes oral (alendronic acid, risedronic acid, ibandronic acid) and parenteral (zoledronic acid, ibandronic acid) preparations. By now, quite large groups of patients with osteoporosis have been taking bisphosphonates for a long time. This fact raises questions about the preservation of the clinical effect, the development of side effects of drugs against the background of prolonged administration, as well as the possibility of cessation or interruption in their use. The document contains recommendations of the experts of the Russian Association for Osteoporosis on the management of patients with osteoporosis receiving bisphosphonate therapy based on the literature review and discussion. The recommended duration of treatment with oral and parenteral bisphosphonates, methods for monitoring the effectiveness of treatment, as well as signs that should be used when deciding on a discontinuation of the therapy or an increase in its duration are formulated. The criteria of ineffectiveness of treatment requiring its correction are discussed. A separate section is devoted to monitoring the patient during a ‘drug holiday’ in taking bisphosphonates and making a decision on resuming treatment. Recommendations are also given for the control and prevention of possible side effects and increasing persistence to bisphosphonate treatment.
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 27 (1) , 4-9
Open AccessThe consensus of experts of the russian association for osteoporosis on the long-term treatment of osteoporosis with bisphosphonates
Bisphosphonates are the most commonly used drugs for the treatment of osteoporosis and reducing the risk of fractures, which were introduced into clinical practice more than 30 years ago. The bisphosphonate group includes oral (alendronic acid, risedronic acid, ibandronic acid) and parenteral (zoledronic acid, ibandronic acid) preparations. By now, quite large groups of patients with osteoporosis have been taking bisphosphonates for a long time. This fact raises questions about the preservation of the clinical effect, the development of side effects of drugs against the background of prolonged administration, as well as the possibility of cessation or interruption in their use. The document contains recommendations of the experts of the Russian Association for Osteoporosis on the management of patients with osteoporosis receiving bisphosphonate therapy based on the literature review and discussion. The recommended duration of treatment with oral and parenteral bisphosphonates, methods for monitoring the effectiveness of treatment, as well as signs that should be used when deciding on a discontinuation of the therapy or an increase in its duration are formulated. The criteria of ineffectiveness of treatment requiring its correction are discussed. A separate section is devoted to monitoring the patient during a ‘drug holiday’ in taking bisphosphonates and making a decision on resuming treatment. Recommendations are also given for the control and prevention of possible side effects and increasing persistence to bisphosphonate treatment.
- Open Access
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 26 (4) , 8-13
Review of recommendations for bisphosphonate treatment interruption-discontinuation
Bisphosphonates are the main medications in the treatment of osteoporosis, which are effective in reducing the risk of fractures in patients with osteoporosis. It is known that after treatment with bisphosphonates, bone mineral density remains quite stable for a certain time, as well as markers of bone metabolism remain reduced, which, along with the side effects of long-term bisphosphonate therapy, determines the possibility of “Drug holidays”. At the same time, during a break in bisphosphonate treatment, the risk of fractures begins to increase, which is a reason to resume therapy.Currently, there is no uniform worldwide data of starting a “drug holidays” on bisphosphonates. The duration of the “drug holidays” also differs in clinical recommendations from different countries. When to conduct a risk assessment of fractures during a “drug holidays”? To answer these questions, we assessed existing clinical recommendations for treatment interruption/discontinuation of bisphosphonates. A literature search was conducted using the following resources: PubMed®, the Cochrane Library, websites of major international osteoporosis associations, and other targeted Internet searches. The main search terms were “Clinical Guideline of Osteoporosis”, “Bisphosphonates”, “Drug holidays in osteoporosis”, “Discontinuation of bisphosphonates”. Тhe search was carried out using articles in Russian and English published between January 1, 2016 and September 15, 2023. 17 clinical guidelines from different countries (Russian, American, European, Asian and Australian) were found and analyzed in which was information about the break in the treatment and withdrawal of bisphosphonates.The majority of clinical recommendations have the same opinion on the issue of starting “drug holidays”: with a moderate risk of fractures, you can take a break from treatment with tableted bisphosphonates after 5 years, after zoledronic acid — after 3 years of therapy. At high and very high risk of fractures, the duration of treatment is 10 and 6 years, respectively. The duration of “drug holidays” vary in the recommendations, but in most cases the decision-making is based not on the duration, but on the assessment of the risk of fractures with their regular reassessment, which includes previous and new low-energy fractures, the emergence of new risk factors, a decrease in BMD, the dynamics of bone markers, re-evaluation of FRAX®.
- 17 April 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 26 (4) , 8-13
Open AccessReview of recommendations for bisphosphonate treatment interruption-discontinuation
Bisphosphonates are the main medications in the treatment of osteoporosis, which are effective in reducing the risk of fractures in patients with osteoporosis. It is known that after treatment with bisphosphonates, bone mineral density remains quite stable for a certain time, as well as markers of bone metabolism remain reduced, which, along with the side effects of long-term bisphosphonate therapy, determines the possibility of “Drug holidays”. At the same time, during a break in bisphosphonate treatment, the risk of fractures begins to increase, which is a reason to resume therapy.Currently, there is no uniform worldwide data of starting a “drug holidays” on bisphosphonates. The duration of the “drug holidays” also differs in clinical recommendations from different countries. When to conduct a risk assessment of fractures during a “drug holidays”? To answer these questions, we assessed existing clinical recommendations for treatment interruption/discontinuation of bisphosphonates. A literature search was conducted using the following resources: PubMed®, the Cochrane Library, websites of major international osteoporosis associations, and other targeted Internet searches. The main search terms were “Clinical Guideline of Osteoporosis”, “Bisphosphonates”, “Drug holidays in osteoporosis”, “Discontinuation of bisphosphonates”. Тhe search was carried out using articles in Russian and English published between January 1, 2016 and September 15, 2023. 17 clinical guidelines from different countries (Russian, American, European, Asian and Australian) were found and analyzed in which was information about the break in the treatment and withdrawal of bisphosphonates.The majority of clinical recommendations have the same opinion on the issue of starting “drug holidays”: with a moderate risk of fractures, you can take a break from treatment with tableted bisphosphonates after 5 years, after zoledronic acid — after 3 years of therapy. At high and very high risk of fractures, the duration of treatment is 10 and 6 years, respectively. The duration of “drug holidays” vary in the recommendations, but in most cases the decision-making is based not on the duration, but on the assessment of the risk of fractures with their regular reassessment, which includes previous and new low-energy fractures, the emergence of new risk factors, a decrease in BMD, the dynamics of bone markers, re-evaluation of FRAX®.
- Open Access
- 18 October 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (5) , 97-106
Efficacy and safety of the combined use of celecoxib, diacerein and a combination of glucosamine and chondroitin for the control of musculoskeletal pain associated with osteoarthritis and nonspecific back pain
The combined use of drugs with different mechanisms of action is the main principle of musculoskeletal pain control in rheumatic diseases. However, there are few studies evaluating the efficacy of this approach in real practice.Objective: to determine the efficacy and safety of the combined use of celecoxib, diacerein, and the combination of glucosamine + chondroitin in osteoarthritis (OA) and chronic nonspecific low back pain (NSLBP). Material and methods. Statistical analysis of data obtained during a 3-month open observational study was performed. We included 1569 patients (63.6 % women and 36.4 % men, mean age 58.7 ± 11.0 years) with knee OA (kOA), hip OA (hOA), generalized OA (gOA), and chronic NSLBP with moderate/severe pain (≥ 4 on a numeric rating scale, NRS 0–10) who required nonsteroidal anti-inflammatory drugs. Celecoxib 200 mg twice daily was prescribed, with the dose reduced to 200 mg per day or taken “as needed" after significant pain relief; diacerein 50 mg twice daily; and a medication of glucosamine 250 mg and chondroitin 200 mg, 2 capsules 2–3 times daily. Outcomes were assessed after 3 months using the dynamics of pain, fatigue, dysfunction (according to NRS), and the “Patient Acceptable Symptom State” (PASS) indicator. Results and discussion. 80.2 % of patients completed the 3 month course of treatment, 4.4 % discontinued treatment due to adverse events (AEs), and for 15.4 % of patients there was no follow-up. After 3 months of treatment ≥ 50 % decrease (from baseline) in the severity of symptoms was noted in 83.4 % of patients for pain on movement, in 83.7 % for pain at rest, in 78.6 % for pain at night, in 80.8 % for dysfunction, and in 83.4 % for fatigue. 87.7 % of patients reported PASS. There were no significant differences in treatment outcomes for different localizations of OA and NSLBP: a ≥ 50 % pain reduction in kOA was achieved in 81.6 % of patients, in hOA – in 82.2 %, in gOA – in 85.0 %, in NSLBP – in 88.1 %. AEs were registered in 350 (22.4 %) patients, the most frequent was dyspepsia (n = 280, 17.8 %), diarrhea was recorded in 37 (2.4 %) cases. No serious AEs requiring hospitalization were registered. Conclusion. Combination therapy with celecoxib, diacerein, and a combination of glucosamine and chondroitin significantly reduces the severity of symptoms of OA and NSLBS.
- 18 October 2023
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (5) , 97-106
Open AccessEfficacy and safety of the combined use of celecoxib, diacerein and a combination of glucosamine and chondroitin for the control of musculoskeletal pain associated with osteoarthritis and nonspecific back pain
The combined use of drugs with different mechanisms of action is the main principle of musculoskeletal pain control in rheumatic diseases. However, there are few studies evaluating the efficacy of this approach in real practice.Objective: to determine the efficacy and safety of the combined use of celecoxib, diacerein, and the combination of glucosamine + chondroitin in osteoarthritis (OA) and chronic nonspecific low back pain (NSLBP). Material and methods. Statistical analysis of data obtained during a 3-month open observational study was performed. We included 1569 patients (63.6 % women and 36.4 % men, mean age 58.7 ± 11.0 years) with knee OA (kOA), hip OA (hOA), generalized OA (gOA), and chronic NSLBP with moderate/severe pain (≥ 4 on a numeric rating scale, NRS 0–10) who required nonsteroidal anti-inflammatory drugs. Celecoxib 200 mg twice daily was prescribed, with the dose reduced to 200 mg per day or taken “as needed" after significant pain relief; diacerein 50 mg twice daily; and a medication of glucosamine 250 mg and chondroitin 200 mg, 2 capsules 2–3 times daily. Outcomes were assessed after 3 months using the dynamics of pain, fatigue, dysfunction (according to NRS), and the “Patient Acceptable Symptom State” (PASS) indicator. Results and discussion. 80.2 % of patients completed the 3 month course of treatment, 4.4 % discontinued treatment due to adverse events (AEs), and for 15.4 % of patients there was no follow-up. After 3 months of treatment ≥ 50 % decrease (from baseline) in the severity of symptoms was noted in 83.4 % of patients for pain on movement, in 83.7 % for pain at rest, in 78.6 % for pain at night, in 80.8 % for dysfunction, and in 83.4 % for fatigue. 87.7 % of patients reported PASS. There were no significant differences in treatment outcomes for different localizations of OA and NSLBP: a ≥ 50 % pain reduction in kOA was achieved in 81.6 % of patients, in hOA – in 82.2 %, in gOA – in 85.0 %, in NSLBP – in 88.1 %. AEs were registered in 350 (22.4 %) patients, the most frequent was dyspepsia (n = 280, 17.8 %), diarrhea was recorded in 37 (2.4 %) cases. No serious AEs requiring hospitalization were registered. Conclusion. Combination therapy with celecoxib, diacerein, and a combination of glucosamine and chondroitin significantly reduces the severity of symptoms of OA and NSLBS.